About Connor Haley
Connor Haley has over a decade of professional investing experience and a passion for investing in undervalued and under-the-radar opportunities. Connor founded Alta Fox Capital in 2018 and is responsible for managing all aspects of the firm’s investment process and strategy. The firm manages several hundred million dollars of assets under management for long-term focused clients.
With Connor Haley at the helm, Alta Fox has established a strong foothold in the industry for its capabilities in deep fundamental analysis and shareholder activism. Over the years, the firm has also built an outstanding track record of effecting significant improvements in the field of corporate governance.
Connor has a lengthy history of serving on public and private company boards. He has been prominently featured in many of the most respected financial publications in the world, including The Wall Street Journal, Bloomberg, and CNBC.
Connor has also been frequently invited to serve as a guest speaker at college investment classes and student-run investment clubs. Most notably, he was a guest lecturer at a Shareholder Activism course hosted by the Columbia Business School.
Educational Background
Connor attended Harvard University, where he graduated magna cum laude with an AB degree in Government studies. He was also an active member of the Harvard Financial Analysts Club, holding respected leadership roles as the club’s Chief Investment Officer and President while winning multiple intercollegiate investing competitions.
Connor Haley’s Professional Achievements
Connor Haley interned in the esteemed Special Situations Group at Goldman Sachs in New York in 2013. In August 2014, he became the first analyst hired directly out of college by Scopia Capital, where he spent four years honing his investment expertise across the Consumer, TMT, and Industrial sectors.
Connor moved back to Texas to launch Alta Fox with an official launch date of April 2018.
To date, Connor remains a managing partner at Alta Fox, which mainly caters to clients in Dallas and Fort Worth.
Alta Fox Capital Management In Profile
Connor founded Alta Fox Capital Management as an alternative asset management company to achieve significant risk-adjusted returns for institutions, family offices, and qualified individual investors.
Utilizing a variety of investment strategies, the firm employs in-depth research and analysis to identify profitable market opportunities while maintaining a disciplined approach to risk management.
The firm’s flagship fund, the Alta Fox Opportunities Fund, was set up to identify little-known and often overlooked investment opportunities in different asset classes, market capitalization sectors, and geographies.
Driven by a diverse and flexible mandate, the fund enables the Alta Fox investment team to pursue high-quality assets at attractive valuations. In this way, it manages to avoid restrictions and traditional hindrances to achieving optimum returns.
Ultimately, Alta Fox focuses on identifying financially stable and well-positioned companies to pursue value-enhancing acquisitions. By targeting businesses with strong fundamentals and strategic growth potential, the firm aims to capitalize on opportunities that drive long-term value creation for investors.
Industry and Peer Recognition
Connor Haley has been widely recognized by industry governing bodies as well as his peers. He was prominently featured in the Co/Investor Club’s list of Top 25 Microcap Managers for his stellar track record of accomplishments with Alta Fox Capital and his other endeavors.
In 2019, Connor pitched at the Texas Hedge Fund Emerging Manager conference. His pitch won first place for both the audience and the judge’s awards. The judges included esteemed investors such as Jim Chanos.
Many of Alta Fox’s research publications, such as “The Makings of a Multibagger,” have garnered widespread industry attention and recognition.
Charitable Works
Connor is a longtime supporter of Breakthrough T1D, a type 1 diabetes research and advocacy organization. The organization is devoted to funding research efforts aimed at developing new treatments and therapies for type 1 diabetes.
